Sarepta Therapeutics (NASDAQ:SRPT) Sets New 12-Month Low – Here’s Why

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price hit a new 52-week low during trading on Monday . The company traded as low as $50.61 and last traded at $52.05, with a volume of 920758 shares trading hands. The stock had previously closed at $54.43.

Analysts Set New Price Targets

Several research firms have weighed in on SRPT. Needham & Company LLC cut their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $161.00 to $87.00 in a report on Monday, March 31st. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. HC Wainwright raised shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price objective for the company in a research note on Wednesday, April 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $163.18.

Sarepta Therapeutics Stock Performance

The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $5.08 billion, a PE ratio of 41.92 and a beta of 0.93. The firm’s 50-day simple moving average is $95.66 and its 200-day simple moving average is $113.09.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Manchester Capital Management LLC lifted its stake in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.